Hepatitis Monthly

Published by: Kowsar

The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection

Zahra Heidari 1 , 2 , Bita Moudi 1 , 2 , * , Hamidreza Mahmoudzadeh-Sagheb 1 , 2 and Mohammad Hashemi 3 , 4
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
4 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Hepatitis Monthly: March 01, 2016, 16 (3); e34266
  • Published Online: March 4, 2016
  • Article Type: Research Article
  • Received: November 1, 2015
  • Revised: January 31, 2016
  • Accepted: February 8, 2016
  • DOI: 10.5812/hepatmon.34266

To Cite: Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H, Hashemi M. The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection, Hepat Mon. 2016 ;16(3):e34266. doi: 10.5812/hepatmon.34266.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008; 359(14): 1486-500[DOI][PubMed]
  • 2. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010; 14(1): 1-21[DOI][PubMed]
  • 3. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000; 15 Suppl-6[PubMed]
  • 4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 5. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis. 1991; 11(2): 84-92[DOI][PubMed]
  • 6. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009; 14(4): 249-58[PubMed]
  • 7. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006; 28: 112-25[DOI][PubMed]
  • 8. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008; 15(2): 137-45[DOI][PubMed]
  • 9. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000; 92(14): 1159-64[PubMed]
  • 10. Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ. Pegylated interferon alpha enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol J. 2012; 9: 274[DOI][PubMed]
  • 11. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003; 98(1): 144-50[DOI][PubMed]
  • 12. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol. 2007; 13(12): 1770-87[PubMed]
  • 13. Deng G, Zhou G, Zhai Y, Li S, Li X, Li Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology. 2004; 40(2): 318-26[DOI][PubMed]
  • 14. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003; 22(33): 5093-107[DOI][PubMed]
  • 15. Juran BD, Lazaridis KN. Genomics and complex liver disease: Challenges and opportunities. Hepatology. 2006; 44(6): 1380-90[DOI][PubMed]
  • 16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 17. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45[DOI][PubMed]
  • 18. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009; 86(1): 23-32[DOI][PubMed]
  • 19. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif. 2008; 41(6): 960-79[DOI][PubMed]
  • 20. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol. 2007; 178(8): 5086-98[PubMed]
  • 21. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008; 7(7): 1109-15[PubMed]
  • 22. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011; 54(4): 716-22[DOI][PubMed]
  • 23. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005; 79(6): 3851-4[DOI][PubMed]
  • 24. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008; 121(5): 1108-11[DOI][PubMed]
  • 25. Uze G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007; 89(6-7): 729-34[DOI][PubMed]
  • 26. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010; 21(4): 237-51[DOI][PubMed]
  • 27. Li MC, Wang HY, Wang HY, Li T, He SH. Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells. Acta Pharmacol Sin. 2006; 27(4): 453-9[DOI][PubMed]
  • 28. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011; 31(8): 1118-26[DOI][PubMed]
  • 29. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801[DOI][PubMed]
  • 30. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006; 80(9): 4501-9[DOI][PubMed]
  • 31. Hashemi M, Moazeni-Roodi A, Bahari A, Taheri M. A tetra-primer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype. Nucleosides Nucleotides Nucleic Acids. 2012; 31(1): 55-60[DOI][PubMed]
  • 32. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J. 2005; 2: 80[DOI][PubMed]
  • 33. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010; 202(11): 1749-53[DOI][PubMed]
  • 34. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther. 2011; 16(5): 629-37[DOI][PubMed]
  • 35. Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, et al. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One. 2012; 7(12)[DOI][PubMed]
  • 36. Lampertico P, Vigano M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013; 57(3): 890-6[DOI][PubMed]
  • 37. Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens. 2012; 79(4): 302-5[DOI][PubMed]
  • 38. Martin-Carbonero L, Rallon NI, Benito JM, Poveda E, Gonzalez-Lahoz J, Soriano V. Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? AIDS Res Hum Retroviruses. 2012; 28(10): 1262-4[DOI][PubMed]
  • 39. Conde SR, Rocha LL, Ferreira VM, Monteiro JC, Filgueiras NK, Lins PA, et al. Absence of correlation between IL-28B gene polymorphisms and the clinical presentation of chronic hepatitis B in an Amazon Brazilian population. Dis Markers. 2014; 2014: 534534[DOI][PubMed]
  • 40. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol. 2013; 28(5): 861-6[DOI][PubMed]
  • 41. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012; 142(3): 513-520 e1[DOI][PubMed]
  • 42. Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res. 2012; 93(2): 297-300[DOI][PubMed]
  • 43. Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, et al. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology. 2013; 56(2): 84-90[DOI][PubMed]
  • 44. Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother. 2012; 61(9): 1433-9[DOI][PubMed]
  • 45. Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L. Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population. Int J Immunogenet. 2012; 39(4): 346-52[DOI][PubMed]
  • 46. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 47. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2): 164-71[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments